Skip to main content
Log in

In Vitro Cytotoxicity of Bismuth-213 (213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells

Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Metastasis is the principal cause of death in breast cancer patients. New and improved treatments for eradicating micrometastases are needed. To this end, a novel α-emitting protein construct, 213Bi-labelled plasminogen activator inhibitor type-2 (PAI-2) (alpha-PAI-2), was evaluated in vitro. This construct exploits: (a) the over-expression of the cell-surface receptor bound urokinase plasminogen activator (uPA) in the metastatic spread of breast cancer cells; (b) the binding and inhibition of receptor-bound uPA by PAI-2; and (c) the high cytotoxicity of alpha radiation. High labeling efficiencies and stability of 213Bi bound to human recombinant PAI-2 conjugated with cyclic diethylenetriaminepentaacetic acid anhydride were achieved (greater than 90%). The uPA inhibitory activity of the chelated PAI-2 was maintained as determined by complex formation with uPA and by inhibition of uPA activity. Furthermore, the reactivity of alpha-PAI-2 was confirmed in a cell assay as this construct was highly cytotoxic to breast cancer cell lines that express active, receptor bound uPA. The specificity of alpha-PAI-2 targeting was shown using several controls. Firstly, an active uPA blocking agent that limits PAI-2 binding significantly improved cell survival by a factor greater than three. Secondly, a non-specific alpha-BSA construct had minimal cytotoxic effect. Moreover, alpha-PAI-2 was not cytotoxic to freshly isolated normal human leukocytes, confirming that cells which do not contain active, receptor bound uPA cannot be targeted by alpha-PAI-2. In conclusion, we have validated, in vitro, the potential of alpha-PAI-2 as a novel therapeutic agent for breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Allen BJ: Can alpha immunotherapy succeed where other systemic therapies have failed? Nucl Med Commun 20: 205–207, 1999

    Google Scholar 

  2. American Cancer Society (ACS): News Today of Breast Cancer Resource Center, June 28, 2000

  3. Raso V: The magic bullet-nearing the century mark. Semin Cancer Biol 1: 227–243, 1990

    Google Scholar 

  4. Allen BJ: Targeted alpha therapy: evidence for efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australas Radiol 43: 480–486, 1999

    Google Scholar 

  5. Allen BJ, Blagojevic N: Alpha and beta emitting radio lanthanides in targeted cancer therapy. Nucl Med Commun 17: 40–47, 1996

    Google Scholar 

  6. Humm JL: A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 13: 1767–1773, 1987

    Google Scholar 

  7. Bloomer WD, McLaughlin WH, Lambrecht RM, Mirzadeh S, Madara JL, Milius RA, Zalutsky MR, Adelstein SJ, Wolf AP: 211At radiocolloid therapy: further observations and comparision with radiocolloids of 32P, 165Dy and 90Y. Int J Radiat Oncol Biol Phys 10:341, 1984

    Google Scholar 

  8. Macklis RM, Beresford BA, Palayoor S, Sweeney S, Humm JL: Cell cycle alterations, apoptosis, and response to low-doserate radioimmunotherapy in lymphoma cells. Int J Oncol 2: 711–715, 1993

    Google Scholar 

  9. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, Landolfi NF, Waldmann TA: Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumour using lead-212-DOTA-AE1. Nucl Med 38: 1944–1950, 1997

    Google Scholar 

  10. Larsen RH, Akabani G, Welsh P, Zalutski MR: The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res 149: 152–157, 1998

    Google Scholar 

  11. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Scheinberg DA: Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 25: 1341–1351, 1998

    Google Scholar 

  12. McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA: An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation. Appl Rad Isot 50: 895–904, 1998

    Google Scholar 

  13. Van Geel JNC, Fuger J, Koch L: Verfahern zur erzeugung von actinium-225 und Bismuth-213 European Patent no. 0 443 479 B1. 1994

  14. Boll RA, Mirzadeh S, Kennel SJ, DePaoli DW, Webb OF: 213Bi for alpha-particle-mediated radioimmunotherapy. J Label Compds Radiopharm 40: 341, 1998

    Google Scholar 

  15. Nikula TK, McDevitt MR, Finn RD: Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 40: 166–176, 1999

    Google Scholar 

  16. Kennel SJ, Stabin M, Roeske JC, Foote LJ, Lankford PK, Terzaghi-Howe M, Patterson H, Barkenbus J, Popp DM, Boll R, Mirzadeh S: Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat Res 151: 244–256, 1999

    Google Scholar 

  17. Kennel SJ, Boll R, Stabin M, Schuller HM, Mirzadeh S: Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi. Br J Cancer 80: 175–184, 1999

    Google Scholar 

  18. Rizvi SM, Sarkar S, Goozee G, Allen BJ: Radioimmunoconjugates for targeted alpha therapy of malignant melanoma. Melanoma Res 10: 281–290, 2000

    Google Scholar 

  19. Adams GP, Shaller CC, Chappell LL, Wu C, Horak M, Simmons HH, Litwin S, Marks JD, Weiner LMN, Brechbiel MW: Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumours by a single-chain Fv and diabody molecules. Nucl Med Biol 27: 339–346, 2000

    Google Scholar 

  20. McDevitt MR, Barendswaard E, Ma D: An alpha-particle emmitting antibody (213Bi-J591) for radioimmunotherapy of prostate cancer. Cancer Res 60: 6095–6100, 2000

    Google Scholar 

  21. Rizvi SMR, Allen BJ, Tian Z, Sarkar S.: In vitro and preclinical studies of targeted alpha therapy for colorectal cancer. Colorectal Disease (in press).

  22. Rizvi SMR, Henniker AJ, Goozee G, Allen BJ: In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes. Leukaemia Res (in press)

  23. Pollanen J, Stephens R, Vaheri A: Directed plasminogen activation at the surface of normal and malignant cells. Adv Cancer Res 57: 273–328, 1991

    Google Scholar 

  24. Andreasen PA, Kjoller L, Christensen L, Duffy M. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22, 1997

    Google Scholar 

  25. Schmitt M, Wilhelm OG, Reuning U: The urokinase plasminogen activation system as a novel target for tumour therapy. Fibrinol Proteol 14: 114–132, 2000

    Google Scholar 

  26. Schmitt M, Janicke F, Chucholowski N, Pache L, Graeff H: Tumour-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe-Seyler 373: 611–622, 1992

    Google Scholar 

  27. Yamamoto M, Sawaya R, Mohanam S: Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumour progression. J Neuro Oncol 22: 139–151, 1994

    Google Scholar 

  28. Mustojoki S, Alitalo R, Stephens RW, Vaheri A: Plasminogen activation in human leukemia and in normal hematopoietic cells. APMIS 107: 144–149, 1999

    Google Scholar 

  29. Dublin E, Hanby A, Patel NK, Liebman R, Barnes D: Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma – fibroblastic expression has strong associations with tumour pathology. Am J Pathol 157: 1219–1227, 2000

    Google Scholar 

  30. Bianchi E, Cohen RL, Thor AT, Todd RF III, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS: The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861–866, 1994

    Google Scholar 

  31. Del Vecchio S, Stoppelli MP, Carriero MV: Human urokinase receptor concnetratin in malignant and benign breast tumours by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 53: 3198–3206, 1993

    Google Scholar 

  32. Christensen L, Wiborg Simonsen AC, Heegaard CW: Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and a2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441–452, 1996

    Google Scholar 

  33. Constantini V, Sidoni A, Deveglia R: Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77: 1079–1088, 1996

    Google Scholar 

  34. Fisher JL, Field CL, Zhou H: Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases – a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Br Cancer Res Treat 61: 1–12, 2000

    Google Scholar 

  35. Kruith EKO, Baker MS, Bunn CL: Biochemistry, cellular and molecular biology and clinical aspects of plasminogen activator inhibitor type-2. Blood 86: 4007–4024, 1995

    Google Scholar 

  36. Hang MTN, Ranson M, Saunders DN, Liang XM, Bunn CL, Baker MS: Pharmacokinetics and biodistribution of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control and tumour xenograft-bearing mice. Fibrinol Proteol12: 145–154, 1998

    Google Scholar 

  37. Andronicos NM, Ranson M, Bognacki J, Baker MS: The human ENO1 gene product (recombinant human alpha-enolase) displays characteristics required for a plasminogen binding protein. Biochimica et Biophysica Acta 1337: 27–39, 1997

    Google Scholar 

  38. Boll RA, Mirzadeh S, Kennel SJ: Optimizations of radiolabeling of immunoproteins with 213Bi. Radiochimica Acta 79: 145–149, 1997

    Google Scholar 

  39. Paik CH, Ebbert MA, Murphy PR, Lassman CR, Reba RC, Eckelman WC, Pak KY, Powe J, Steplewski K: Factors in-fluencing DTPA conjugation with antibodies by cyclic DTPA anhydride. J Nucl Med 24: 1158–1163, 1983

    Google Scholar 

  40. Bennett KL, Sheil MM: Probing the coordination of metal ions by diethylenetriaminepentacetic acid-conjugated proteins with electrospray ionisation mass spectrometry. Eur Mass Spectrum 3: 233–244, 1997

    Google Scholar 

  41. Ranson M, Andronicos N, O'Mullane, Baker MS: Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br J Cancer 77: 1586–1597, 1998

    Google Scholar 

  42. Laug WE, Cao XR, Yu YB, Shimada H, Kruithof EKO: Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 53: 6051–6057, 1993

    Google Scholar 

  43. Mueller BA, Yu YB, Laug WE: Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 92: 205–209, 1995

    Google Scholar 

  44. Evans DM, Lin PL: Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am Surgeon 61: 692–696, 1995

    Google Scholar 

  45. Yang J-L, Seetoo D, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ: Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer specific survival, and potential therapeutic targets. Intl J Cancer 89: 431–439, 2000

    Google Scholar 

  46. Jankun J: Antitumour activity of the type 1 plasminogen activator inhibitor and cytotoxic conjugate in vitro. Cancer Res52: 5829–5832, 1992

    Google Scholar 

  47. Jankun J: Targeting of drugs to tumours: the use of the plasminogen activator inhibitor as a ligand. In: Gregoriadis G et al. (eds) Targeting of Drugs 4. Plenum Press, New York, 1994, pp. 67–79

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ranson, M., Tian, Z., Andronicos, N. et al. In Vitro Cytotoxicity of Bismuth-213 (213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells. Breast Cancer Res Treat 71, 149–159 (2002). https://doi.org/10.1023/A:1013850107791

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013850107791

Navigation